"Chemobrain"revisión de estudios que evalúan el deterioro cognitivo de superviventes de cáncer tratados con quimioterápia

  1. López Santiago, Sonia
  2. Cruzado Rodríguez, Juan Antonio
  3. Feliu Batlle, Jaime
Revista:
Psicooncología: investigación y clínica biopsicosocial en oncología

ISSN: 1696-7240

Año de publicación: 2011

Volumen: 8

Número: 2-3

Páginas: 265-280

Tipo: Artículo

DOI: 10.5209/REV_PSIC.2011.V8.N2-3.37881 DIALNET GOOGLE SCHOLAR lock_openAcceso abierto editor

Otras publicaciones en: Psicooncología: investigación y clínica biopsicosocial en oncología

Resumen

Planteamiento del problema: Algunos pacientes oncológicos han expresado problemas de atención, concentración y memoria durante y después de los tratamientos con quimioterapia, a los que se ha llamado chemobrain. Como consecuencia de estas manifestaciones, en las últimas décadas los estudios dedicados a indagar este posible efecto adverso se han incrementado. Desarrollo del tema: Este trabajo pretende revisar y analizar los estudios científicos más recientes que investigan la naturaleza y alcance del daño cognitivo asociado a los tratamientos quimioterapéuticos. Los artículos analizados se han extraído de diferentes fuentes bibliográficas, principalmente de la base de datos PubMed. Como resultado de la búsqueda se aprecia que, en los últimos años, se han incremento los estudios de diseño longitudinal; este posible efecto adverso se sigue estudiando sobre todo en muestras de mujeres con cáncer de mama, las investigaciones en otros tipos de cánceres son insuficientes; así mismo, destaca la inclusión de nuevas herramientas de evaluación, como la resonancia magnética y el electroencefalograma, junto con nuevos experimentos realizados con animales, in vivo e in vitro, finalmente se constata la inclusión de algunos estudios sobre fármacos y estrategias eficaces para su afrontamiento. La elaboración de guías para el estudio sistemático y las re- comendaciones para su abordaje aún quedan pendientes. Conclusiones: no existen datos concluyentes sobre el chemobrain, los estudios longitudinales deberán incentivarse, así como la valoración del impacto cognitivo de determinados esquemas quimioterapéuticos en diferentes cánceres. Los trabajos sobre el afrontamiento, psicológico y/o farmacológico, de este problema deben continuar.

Referencias bibliográficas

  • 1. Rubio B, Sirgo A, Forcadell E, Mele M, Guma J. Deterioro cognitivo inducido por los tratamientos oncológicos sistémicos en el cáncer de mama no metastático: revisión de estudios. Psicooncología 2009; 6: 83-120.
  • 2. López S, Cruzado JA, Feliu J. Rendimiento cognitivo, estado emocional y calidad de vida en pacientes de cáncer de colon previamente a recibir tratamiento de quimioterapia. Psicooncología 2009; 6: 121-37.
  • 3. Vardy J. Neurocognitive effects of chemotherapy in adults. Aust Prescr 2008; 31: 22-24.
  • 4. Argyriou A, Assimakopoulos K, Iconomou G, Giannakopoulou F, Kalofonos H. Either caller “chemobrain” or “chemofog”, the long-term chemotherapy-induced cognitive decline in cancer survivors is real. J Pain Symptom Manage 2010 : 41 : 126-39. Doi : http://dx.doi.org/10.1016/j.jpainsymman.2010.04.021
  • 5. Hess LM, Insel KC. Chemotherapy-related change in cognitive function: a conceptual model. Oncol Nurs Forum 2007; 34: 981-94. Doi:10.1188/07.ONF.981-994
  • 6. Rodin MB, Wallace JA, Lacy M, Kuball K, Pykkonen B, Freming G. Does adjuvant chemotherapy (CT) exacerbate cognitive impairment in elderly breast cancer (BC) patients? Results of a prospective, longitudinal study. J Clin Oncol 2006; 24 (20 Supplement): 10530.
  • 7. Vardy J, Wong K, Yi Q, Park A, Maruff P, Wagner L et al. Assessing cognitive function in cancer patients. Support Care Cancer 2006; 14: 1111-18. Doi:10.1007/s00520-006-0037-6
  • 8. Wefel JS, Saleeba AK, Buzdar AU, Meyers CA. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 2010; 116: 3348-56. Doi:10.1002/cncr.25098
  • 9. Hurria A, Somlo G, Ahles T. Renaming “chemobrain”. Cancer Invest 2007; 23: 373-7. Doi:10.1080/07357900701506672
  • 10. Bender CM, Sereika SM, Berga SL, Vogel VG, Brufsky AM, Paraska KK et al. Cognitive impairment associated with adjuvant therapy in breast cancer. Psychooncology 2006; 15: 422-30. Doi:10.1002/pon.964
  • 11. Collins B, Mackenzie J, Stewart A, Bielajew C, Verma S. Cognitive effects of chemotherapy in post-menopausal breast cancer patients 1 year after treatment. Psychooncology 2009; 18: 134-43. Doi:10.1002/pon.1379
  • 12. Correa DD, Ahles TA. Cognitive adverse effects of chemotherapy in breast cancer patients. Cur Opin Support Palliat Cancer 2007; 1: 57-62. Doi:10.1097/SPC.0b013e32813a328f
  • 13. Wagner LI, Sweet JJ, Butt Z, Beaumont J, Havlin KA, Sabatino T et al. Trajectory of cognitive impairment during breast cancer treatment: a prospective analysis. J Clin Oncol, 2006; 24 (20 Suppl): 8500.
  • 14. Jansen CE, Dodd M, Miaskowski CA, Dowling GA, Kramer J. Preliminary results of a longitudinal study of changes in cognitive function in breast cancer patients undergoing chemotherapy with doxorubicin and cyclophosphamide. Psychooncology, 2008; 17: 1189-95. Doi:10.1002/pon.1342
  • 15. Ahles TA, Saykin AJ, McDonald BC, Li Y, Furstenberg CT, Hanscom BS et al. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol 2010; 28: 4434-40. Doi:10.1200/JCO.2009.27.0827
  • 16. Schagen SB, Muller MJ, Boogerd W, Mellenbergh GJ, van Dam FSAM. Change in cognitive function after chemotherapy: A prospective longitudinal study in breast cancer patients. J Natl Cancer Inst 2006; 98: 1742-45. Doi:10.1093/jnci/djj470
  • 17. Stewart A, Collins B, Mackenzie J, Tomiak E, Verma S, Bielajew C. The cognitive effects of adjuvant chemotherapy in early stage breast cancer: a prospective study. Psychooncology 2008; 17: 122-30. Doi:10:1002/pon.1210
  • 18. Quesnel C, Savard J, Ivers H. Cognitive impairments associated with breast cancer treatments: results from a longitudinal study. Breast Cancer Res Treat 2009; 116: 113-23. Doi:10.1007/s10549-008-0114-2
  • 19. Ahles TA, Saykin AJ, McDonald BC, Furstenberg CT, Cole BF y Hanscom BS. Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat 2008; 110: 143-52. Doi:10.1007/s10549-007-9686-5
  • 20. Hurria A, Goldfarb S, Rosen C, Holland J, Zuckerman E, Lachs MS et al. Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient’s perspective. Breast Cancer Res Treat 2006; 98: 343-8. Doi:10.1007/s10549-006-9171-6
  • 21. Shilling V, Jenkins V. Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. Eur J Oncol Nurs 2007; 11: 6-15. Acceso el 12 de Agosto, 2010. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/16844416 Doi:10.1016/j. ejon.2006.02.005
  • 22. Jenkins V, Shilling V, Deustsch G, Bloomfield D, Morris R, Allan S et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer 2006; 94: 828-34. Doi.10.1030/sj.bjc.6603029
  • 23. Mehlsen M, Pedersen AD, Jensen AB, Zachariae R. No indications of cognitive side-effects in a prospective study of breast cancer patients receiving adjuvant chemotherapy. Psychooncology 2009; 18, 248-57. Doi:10.1002/pon.1398
  • 24. Tager FA, Mckinley PS, Schnabel FR, El-Tamer M, Cheung YKK, Fang Y et al. The cognitive effects of chemotherapy in post-menopausal breast cancer patients: a controlled longitudinal study. Breast Cancer Res Treat 2010; 123: 25-34. Doi:10.1007/s10549-009-0684-7
  • 25. Eberhardt B, Dilger S, Musial F, Wedding U, Weiss T, Miltner WHR. Short-term monitoring of cognitive functions before and during the first course of treatment [Abstract]. J Cancer Res Clin Oncol 2006; 132: 234-40. Doi:10.1007/s00432-005-0070-8
  • 26. Eberhardt B, Dilger S, Musial F, Wedding U, Weiss T, Miltner WHR. Medium-term effects of chemotherapy in older cancer patients. Support Care Cancer 2006; 14: 216-22. Doi:10.1007/s00520-005-0894-4
  • 27. Mancuso A, Migliorino M, De Santis S, Saponiero A, De Marinis F. Correlation between anemia and fuctional/cognitive capacity in elderly lung cancer patients treated with chemotherapy. Ann Oncol 2006; 17:146-50. Doi:10.1093/annonc/mdj038
  • 28. Vardy J, Rourke S, Pond GR, Galica J, Park A, Dhillon H, et al. Cognitive function and fatigue in cancer patients after chemotherapy: a longitudinal cohort study in patients with colorectal cancer (CRC). J Clin Oncol 2007: 25 (Meeting Abstracts) (18): Suppl 9099
  • 29. Vardy JL, Xu W, Booth CM, Park A, Dodd A, Rourke S et al. Relation between perceived cognitive function and neuropsychological performance in survivors of breast and colorectal cancer. J Clin Oncol 2008; 26 (Meeting Abstracts) (15): Suppl 9520
  • 30. Vardy J, Dhillon H, Xu W, Dodd A, Park A, Rourke SB, et al. Cognitive function and fatigue in colorectal cancer (CRC) patients: Baseline assessments prior to chemotherapy. J Clin Oncol 2009; 27 (Meeting Abstracts) (15): Suppl 9557
  • 31. Schagen SB, Boogerd W, Muller MJ, Huinink WT, Moonen L, Meinhardt W et al. Cognitive complaints and cognitive impairment following BEP chemotherapy in patients with testicular cancer. Acta Oncol 2008; 47: 63-70. Doi:10.1080/02841860701518058
  • 32. Wefel, Vidrine, Veramonti, Meyers, Marani, Hoekstra et al. Cognitive impairment in men with testicular cancer prior to adjuvant therapy. Cancer 2011; 117: 190-6. Doi.10.1002/cncr.25298
  • 33. Myers JS, Sousa VD y Donovan HS. Predictors of self-reported memory problems in patients with ovarian cancer who have received chemotherapy. Oncol Nurs Forum 2010; 35: 596-603. Doi:10.1188/10.ONF.596-603
  • 34. Winocur G, Vardy J, Binns MA, Kerr L y Tannock I. The effects of the anti-cancer drugs, methotrexate and 5-fluorouracil, on cognitive function in mice [Abstract]. Pharmacol Biochem Behav, 2006; 85: 65-75. Doi:10.1016/j.pbb.2006.07.010
  • 35. Lee GD, Longo DL, Wang Y, Rifkind JM, Abdul-Raman L, Mamczarz JA et al. Transient improvement in cognitive function and synaptic plasticity in rats following cancer chemotherapy. Clin Cancer Res 2006; 12: 198-205. Doi:10.1158/1078-0432.CCR-05-1286
  • 36. Reiriz AB, Reolon GK, Preissles T, Rosado JO, Henriques JAP, Roesler R et al. Letter to the Editor: Cancer chemotherapy and cognitive function in rodent models: memory impairment induced by cyclophosphamide in mice. Clin Cancer Res 2006; 12: 5000-1.
  • 37. Tangpong J, Cole MP, Sultana R, Estus S, Vore M, St. Clair W et al. Adriamycin-mediated nitration of manganese superoxide dismutase in the central nervous system: Insight into the mechanism of chemobrain. J Neurochem 2007; 100: 191-201. Doi:10.1111/j.1471-4159.2006.04179.x
  • 38. Konat GW, Kraszpulski M, James I, Zhang H-T y Abraham J. Cognitive dysfunction induced by chronic administration of common cancer chemotherapeutics in rats. Metab Brain Dis 2008; 23: 325-33. Doi:10.1007/11011-008-9100-y
  • 39. Gandul MJ, Ehrlichman RS, Rudnick N, Siegel SJ. A novel electrophysiological model of chemotherapy-induced cognitive impairments in mice. Neuroscience 2008; 157: 95-104. Doi:10.1016/j.neuroscience.2008.08.060
  • 40. Foley JJ, Raffa RB, Walter EA. Effects of chemotherapeutic agents 5-fluorouracil and methotrexate alone and combined in a mouse model of learning and memory. Psychopharmacology 2008; 199: 527-38. Doi:10.1007/s00213-008-1175-y
  • 41. Fardell JE, Vardy J, Logge W, Johnston I. Single high dose treatment with methotrexate causes long-lasting cognitive dysfunction in laboratory rodents. Pharmacol, Bioschem Behav 2010; 97: 333-39. Doi:10.1016/j.pbb.2010.08.019
  • 42. Dietrich J, Han R, Yang Y, Mayer-Pröschel M, Noble M. CNS progenitor cells and aligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol, 2006; J Biol. 2006; 5: 22.1–22. [En línea] [Acceso el 12 de noviembre, 2008]. Disponible en: http://jbiol.com/content/pdf/jbiol50.pdf
  • 43. Schagen SB, Dam FS, van Dam Does cognitive impairment after chemotherapy for breast cancer improve over time or does practice make perfect? J Clin Oncol 2006; 24: 5170-1. Doi:10.1200/JCO.2006.07.8303
  • 44. Swayampakula AK, Alkhouri N, Haut MW, Abraham J. Cognitive impairment with significant brain parenchymal volume loss following standard adjuvant chemotherapy in a patient with breast cancer. Clin Adv Hematol Oncol 2007; 5: 985-7.
  • 45. Ferguson RJ, McDonald BC, Saykin AJ, Ahles TA. Brain structure and function differences in monozygotic twins: Possible effects of breast cancer chemotherapy. J Clin Oncol 2007; 25: 3866-70. Doi:10.1200/JCO.2007.10.8639
  • 46. Booth CM, Vardy J, Crawley A, Rourke S, Pond G, Wagner L, et al. Cognitive impairment associated with chemotherapy for breast cancer: an exploratory case-control study [Abstract]. J Clin Oncol 2006; 24 (18 Suppl): 8501.
  • 47. Inagaki M, Yoshikawa E, Matsuoka Y, Sugawara Y, Nakano T, Akechi T, et al. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer 2007; 109: 146-56. Doi:10.1002/cncr.22368
  • 48. Silverman CJ, Steven CJ, Castellon SA, Lai J, Pio BS, Abraham L, et al. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res Treat 2007; 103, 303-11. Doi:10.1007/s10549-006-9380-z
  • 49. Abraham J, Aut, MW, Moran MT, Filburn S, Lemiuex S. Kuwabara H. Adjuvant chemotherapy for breast cancer: effects on cerebral white matter seen in diffusion tensor imaging. Clin Breast Cancer 2008; 8: 88-91. Doi:10.3816/CBC.2008.n.007
  • 50. McDonald BC, Conroy SK, Ahles T, West JD, Saykin AJ. Gray matter reduction associated with systemic chemotherapy for breast cancer: A Prospective MRI study [Abstract]. Breast Cancer Res Treat 2010; 123: 819-28. Doi:10.1007/s10549-010-1088-4
  • 51. Kreukels VPC, Schagen SB, Ridderinkhof KR, Boogerd W, Hamburger HL, Muller MJ et al. Effects of high-dose and conventionaldose adjuvant chemotherapy on long-term cognitive sequelae in patients with breast cancer: an electrophysiologic study. Clin Breast Cancer 2006; 7: 67-8. Doi:10.3816/CBC.2006.n.015
  • 52. Kreukels BPC, Hamburger HL, Ruiter MB, van Dam FSAM, Ridderinkhof KR, Boogerd W, et al. ERP amplitude and latency in breast cancer survivors treated with adjuvant chemotherapy. Clin Neurophysiol 2008; 119: 533-41. Doi:10.1016/j.clinph.2007.11.011
  • 53. Ahles T, Saykin A. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer 2007; 7: 192-201. Doi:10.1038/nrc2073
  • 54. O’Shaughnessy JA, Vukelja SJ, Holmes FA, Savin, M, Jones M, Royall D et al. Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy. Clin Breast Cancer 2005; 5: 439-46. Doi:10.3816/CBC.2005.n.002
  • 55. Iconomou G, Koutras A, Karaivazoglou K, Kalliolias GD, Assimakopoulos K, Argyriou AA et al. Effect of epoetin alpha therapy on cognitive function in anaemic patients with solid tumours undergoing chemotherapy. Eur J Cancer Care 2008; 17: 535-41. Doi:10.1111/j.1365-2354.2007.00857.x
  • 56. Massa E, Madeddu C, Lusso MR, Gramignano G, Mantovani G. Evaluation of the effectiveness of treatment with erythropoietin on anemia, cognitive functioning and functions studied by comprehensive geriatric assessment in elderly cancer patients with anemia related to cancer chemotherapy. Crit Rev Oncol Hematol 2006; 57: 175-82. Doi.10.1016/j.critrevonc.2005.06.001
  • 57. Kohli S, Fisher SG, Tra Y, Adams MJ, Mapstone MG, Wesnes KA et al. The effect of modafinil on cognitive function in breast cancer survivors. Cancer 2009; 115: 2605-16. Doi:10.1002/cncr.24287
  • 58. Mar Fan HG, Clemons M, Xu W, Chemerynsky I, Breunis H, Braganza S, et al. A randomised, placebo-controlled, double-bling trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Support Care Cancer 2008; 16: 364-71. Doi:10.1007/s00520-007-0341-9
  • 59. Joshi G, Hardas S, Sultana R, St. Clair DK, Vore M, Butterfield DA. Glutathione elevation by γ-glutamyl cysteine ethyl ester as a potential therapeutic strategy for preventing oxidative strees in brain mediated by in vivo administration of adriamycin: Implication for chemobrain. J Neurosci Res 2007; 85: 497-503. Do1: 10.1002/jnr.21158
  • 60. Mustafa S, Umka J, Lyons L, Salman A, Chur-yoe GT, Bhalla N et al. Fluoxeti-ne improves the memory deficits caused by the chemotherapy agent 5-fluoroura-cil. Behav Brain Res 2010; 208: 112-17. Doi:10.1016/j.bbr.2009.11.017
  • 61. Ferguson RJ, Ahles TA, Saykin AJ, Mc-Donald BC, Furstenberg, CT, Cole BF et al. Cognitive-behavioural management of chemotherapy-related cognitive chan-ge. Psychooncology 2007; 16: 772-777. Doi:10.1002/pon.1133
  • 62. Ferguson RJ, McDonald BC, Rocque MA, Furstenberg CT, Horrigan S, Ahles TA, Say-kin AJ. Development of CTB for chemothe-rapy-related cognitive change: results of a waitlist control trial. Psychooncology 2010. Doi:10.1002/pon.1878
  • 63. Biegler KA, Chaoul MA, Cohen L. Can-cer, cognitive impairment, and medi-tation. Acta Oncol 2009; 48: 18-26. Doi:10.1080/02841860802415535
  • 64. Poppelreuter M, Weis J, Bartsch HH. Effects of specific neuropsychological training pro-grams for breast cancer patients after adjuvant chemotherapy. J Psychosoc Oncol 2009; 2: 274-96. Doi:10.1080/07347330902776044
  • 65. Vardy J, Rourke S, Tannock IF. Evaluation of cognitive function associated with chemotherapy: A review of published studies and recommendations for future research. J Clin Oncol 2007; 25: 2455-63. Doi:10.1200/2006.08.1604
  • 66. Shilling V, Jenkins V, Trapala IS. The (mis) classification of chemo-fog-methodological inconsistencies in the investigation of cognitive impairment after chemotherapy. Breast Cancer Res Treat 2006; 95: 125-9. Doi:10.1007/s10549-005-9055-1
  • 67. Tannock IF, Ahles TA, Ganz PA, van Dam FS. Cognitive impairment associated with chemotherapy for cancer: Report of a Workshop. J Clin Oncol 2004; 22: 2233-9. Doi:10.1200/JCO.2004.08.094
  • 68. Vardy J, Wefel JS, Ahles T, Tannock IF, Schagen SB. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol 2008; 19: 623-29 Doi:10.1093/annonc/mdm500
Fuente de los datos: Dialnet